Full Answer
The MAT waiver training for PAs consists of two components; Part 1 is the 8-hour physician training program and Part 2 is the 16 hours of additional training required by CARA 2016.
The MAT waiver training available from ASAM and PCSS are approved for 24 hours of Category I CME by the AAPA. Students cannot submit the training for CME credit retroactively. 5. My program considered participating in a SAMHSA grant for the waiver training, as any NP or PA can take the 24-hour waiver training.
8 Hour Training + 16 Hour Training = 24 Hours of Education Required to Obtain a DEA MAT Waiver for More Than 30 Patients Register now for these 2 FREE courses on medications for addictions treatment (MAT) and:
If the waiver training is made a required assignment, students who do not complete the training should be subject to whatever the program policy is on non-completion of program requirements. 1.
Medication for Addictions Treatment Training for Nurses Complete 24 hours of education required to obtain a DEA waiver to prescribe MAT (including buprenorphine) for opioid use disorders for more than 30 patients.
The American Academy of Physician Assistants approved MAT waiver training for 24 hours of category I CME credits.
Nurse practitioners are newly allowed to prescribe buprenorphine (Suboxone) as part of the Comprehensive Addiction and Recovery Act signed into law by former President Obama.
Subutex® and Suboxone® have received FDA approval only for the treatment of opioid addiction. However, once approved, a drug product may be prescribed by a licensed physician for any use that, based on the physician's professional opinion, is deemed to be appropriate.
These MAT medications are safe to use for months, years, or even a lifetime. As with any medication, consult your doctor before discontinuing use.
A Data 2000 Waiver refers to the Drug Addiction Treatment Act (DATA 2000) "waiver" legislation that authorized the outpatient use of buprenorphine for the treatment of OUD. The DATA 2000 Waiver helps improve access to OUD and substance-use disorder (SUD) treatment.
Practitioners at the 30- and 100-level do not need to renew their waivers. Practitioners who are at the 275-patient limit need to renew their patient limit every 3 years and submit a yearly report annually.
Physician Assistants (PAs) and Advanced Registered Nurse Practitioners (ARNPs) can prescribe controlled substances listed in Schedule II, Schedule III or Schedule IV as defined in s. 893.03 Florida Statutes, beginning January 1, 2017.
456.42, Florida Statutes? A: Allopathic prescribing practitioners (MD), osteopathic prescribing practitioners (OS), podiatric prescribing practitioners (PO), Dentists (DMD or DDS), optometrists (DO), physician assistants (PA), and Advanced Practitioner Registered Nurses (APRN).
The new rule means nearly all doctors can prescribe buprenorphine, also called by brand name Suboxone. Previously, most doctors had to seek a special waiver and have an eight hour training to be approved to do so and now physicians can prescribe regardless of if they get that training.
The short answer to this question is yes. You can access medication-assisted treatment via telemedicine.
Yes, Suboxone can be called into a pharmacy.
Florida's Nurse Practitioner Prescribing Laws Florida is one of just two states that does not allow nurse practitioners to prescribe controlled substances even with physician supervision. Legislators in Florida recognize that some practices may attempt to circumvent this law.
Florida Yes. An APRN may prescribe only within the framework of an established protocol, however, NPs with at least 3,000 clinical practice hours and certain graduate level coursework and working in primary care practice may prescribe without collaborative agreement.
Family nurse practitioners receive advanced clinical training and education in order to provide a wider range of care to patients than registered nurses. Duties can include diagnosing patients, ordering and interpreting tests, and prescribing medications.
As a friendly reminder, Florida ARNPs are not authorized to prescribe controlled substances and thus cannot initiate, scribe, order or have this authority delegated by a DEA licensed professional to prescribe a controlled substance in any class.
The initial 8-hour training may be provided in a face-to-face format or a hybrid 4-hour in-person session with the last four hours completed online. Check the websites of the DATA 2000 sponsors of waiver training for a course near you. Once you’ve completed the 8-hour physician training block, you can complete the 16-hours of additional CARA required online.
Appendix M for Self Study Report. ARC-PA requires all program changes to be reported in Appendix M when a self-study document is submitted. Here is suggested documentation when you add MAT training to your program.
MAT is the use of medications to treat persons with opiate use disorder. The three medications approved by the FDA for MAT are methadone, buprenorphine, and naltrexone.
The MAT waiver training available from ASAM and PCSS are approved for 24 hours of Category I CME by the AAPA. Students cannot submit the training for CME credit retroactively.
If the waiver training is made a required assignment, students who do not complete the training should be subject to whatever the program policy is on non-completion of program requirements.
Having students complete the training early in the clinical year may have the advantage of proximity to didactic learning and give students an opportunity to practice some of the skills they will develop from the training during their SCPEs.
Completion of Part 1 training may be accomplished in several different ways: in an 8-hour face-to-face format, a hybrid of 4 hours face-to-face and 4 hours online, or completely online. At this time, Part 2 is available only as online training modules.
Yes, both the training from the ASAM and PCSS require the participant to successfully complete a quiz at the end of each module before progressing. Students could submit a screen shot of the quiz score report for tracking purposes.
Yes, the training isn’t limited to prescribers. All PAs, regardless of their specialty, will benefit by enhancing their ability to recognize patients at risk of opioid misuse or abuse, diagnose patients with opioid use disorder, and identify what treatment options are available. 7.
There are likely students whose supervised clinical practice experience (SPCE) includes a primary care office that provides MAT, but the extent is unknown. There is no requirement to have clinical experience with MAT in order to get the waiver. 3.
The ultimate goal of MAT is full recovery, including the ability to live a self-directed life. This treatment approach has been shown to: 1 Improve patient survival 2 Increase retention in treatment 3 Decrease illicit opiate use and other criminal activity among people with substance use disorders 4 Increase patients’ ability to gain and maintain employment 5 Improve birth outcomes among women who have substance use disorders and are pregnant
Medications used in MAT are approved by the Food and Drug Administration (FDA) and MAT programs are clinically driven and tailored to meet each patient’s needs. Research shows that a combination of medication and therapy can successfully treat these disorders, and for some people struggling with addiction, MAT can help sustain recovery.
Contact Us. For information on buprenorphine waiver processing, contact the SAMHSA Center for Substance Abuse Treatment (CSAT) at 866- BUP-CSAT (866-287-2728) or [email protected]. (link sends email)
For assistance with the Opioid Treatment Program Extranet, contact the OTP helpdesk at [email protected]. (link sends email) or 1-866-348-5741. Contact SAMHSA’s regional OTP Compliance Officers to determine if an OTP is qualified to provide treatment for substance use disorders. Last Updated.
Medication-assisted treatment (MAT) is the use of medications, in combination with counseling and behavioral therapies, to provide a “whole-patient” approach to the treatment of substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA) and MAT programs are clinically driven and tailored ...
These MAT medications are safe to use for months, years, or even a lifetime. As with any medication, consult your doctor before discontinuing use. Learn more about MAT for opioid use disorders.
For information about other medication-assisted treatment (MAT) or the certification of opioid treatment programs (OTPs), contact the SAMHSA Division of Pharmacologic Therapies at 240-276-2700. [email protected]. (link sends email)